



Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development

Guest Editor:

Dr. Jianhui Nie

Division of HIV/AIDS and Sex-
Transmitted Virus Vaccines,
National Institutes for Food and
Drug Control, Beijing 102629,
China

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Neutralizing antibodies are important indicators for the evaluation of the effectiveness of SARS-CoV-2 vaccines. At present, there are many methods for detecting SARS-CoV-2 neutralizing antibodies, including culture live virus neutralization method, recombinant replication virus neutralization method, pseudotyped virus neutralization method, and competition inhibition neutralization antibody detection method. Even if the same type of method is used, specific operations in different laboratories can lead to differences in results. As a result, the neutralizing antibody test results of different vaccines are incomparable, meaning that the immunogenicity of different vaccines cannot be compared horizontally.

In this Special Issue, original research articles and reviews are welcome, include (but are not limited to) the following: (i) recent advances in novel neutralization assay development, (ii) standardization and comparison of different SARS-CoV-2 neutralization assays, (iii) comparison of neutralizing antibody responses induced by different vaccines, and (iv) correlates of protection.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com